GEP20156267B - 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES - Google Patents

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Info

Publication number
GEP20156267B
GEP20156267B GEAP201012484A GEAP2010012484A GEP20156267B GE P20156267 B GEP20156267 B GE P20156267B GE AP201012484 A GEAP201012484 A GE AP201012484A GE AP2010012484 A GEAP2010012484 A GE AP2010012484A GE P20156267 B GEP20156267 B GE P20156267B
Authority
GE
Georgia
Prior art keywords
imidazo
quinolinone derivatives
unsubstituted
substituted
quinolinone
Prior art date
Application number
GEAP201012484A
Other languages
English (en)
Inventor
Pascal Furet
Frank Stephan Kalthoff
Robert Mah
Christian Ragot
Frédéric Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20156267(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GEP20156267B publication Critical patent/GEP20156267B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GEAP201012484A 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES GEP20156267B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
GEP20156267B true GEP20156267B (en) 2015-04-14

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201012484A GEP20156267B (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Country Status (30)

Country Link
US (2) US8476294B2 (enExample)
EP (1) EP2438064A1 (enExample)
JP (1) JP5596137B2 (enExample)
KR (1) KR101445458B1 (enExample)
CN (1) CN102574845B (enExample)
AR (1) AR076949A1 (enExample)
AU (1) AU2010255727B2 (enExample)
BR (1) BRPI1010621A2 (enExample)
CA (1) CA2763821A1 (enExample)
CL (1) CL2011003052A1 (enExample)
CO (1) CO6470887A2 (enExample)
CR (1) CR20110608A (enExample)
CU (1) CU24064B1 (enExample)
DO (1) DOP2011000373A (enExample)
EA (1) EA020715B1 (enExample)
EC (1) ECSP11011500A (enExample)
GE (1) GEP20156267B (enExample)
IL (1) IL216452A0 (enExample)
MA (1) MA33332B1 (enExample)
MX (1) MX2011012943A (enExample)
NI (1) NI201100209A (enExample)
NZ (1) NZ596487A (enExample)
PE (1) PE20120224A1 (enExample)
SG (1) SG176572A1 (enExample)
TN (1) TN2011000626A1 (enExample)
TW (1) TWI464168B (enExample)
UA (1) UA106074C2 (enExample)
UY (1) UY32682A (enExample)
WO (1) WO2010139731A1 (enExample)
ZA (1) ZA201108439B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
KR20140014104A (ko) * 2010-12-06 2014-02-05 피라말 엔터프라이지즈 리미티드 치환된 이미다조퀴놀린 유도체
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
JP5820080B2 (ja) * 2011-11-17 2015-11-24 山▲東▼▲軒▼竹医▲葯▼科技有限公司 三環系PI3K及び/又はmTOR抑制剤
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
BR112015025686B1 (pt) 2013-04-15 2020-10-27 Fmc Corporation composto, composições fungicidas e método para o controle das doenças dos vegetais
JP6576929B2 (ja) * 2013-09-11 2019-09-18 メルク パテント ゲーエムベーハー ヘテロ環化合物
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
US10989719B2 (en) * 2013-10-11 2021-04-27 National University Corporation Tokyo Medical And Dental University Methods for treating spinocerebellar ataxia type I using RPA1
CA2931147C (en) * 2013-11-20 2018-05-29 Beijing Forelandpharma Co. Ltd. Imidazolone derivatives, pharmceutical compositions and uses thereof
NO2714752T3 (enExample) 2014-05-08 2018-04-21
JP6195684B2 (ja) 2014-06-03 2017-09-13 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用
DK3560924T3 (da) * 2015-04-02 2021-06-28 Merck Patent Gmbh Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
CA3050348A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
EP4142710B1 (en) 2020-09-21 2024-01-31 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
US20230380203A1 (en) * 2021-01-26 2023-11-23 Boe Technology Group Co., Ltd. Quantum dot light-emitting device, display apparatus and manufacturing method
JP2024534187A (ja) * 2021-08-31 2024-09-18 インサイト・コーポレイション Krasの阻害剤としてのナフチリジン化合物
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
CN117384154A (zh) * 2023-09-04 2024-01-12 广州医科大学 一种吡咯并喹啉酮化合物、合成方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2007511575A (ja) 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての1h−イミダゾキノリン誘導体
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CN101056877B (zh) 2004-09-14 2010-06-09 诺华疫苗和诊断公司 咪唑并喹啉化合物
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
KR20090080530A (ko) 2006-11-20 2009-07-24 노파르티스 아게 2-메틸-2-[4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조[4,5-c]퀴놀린-1-일)-페닐]-프로피오니트릴의 염 및 결정 형태
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
EP2474323A3 (en) 2008-03-26 2012-10-10 Novartis AG Imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
WO2010038165A1 (en) 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
CR20110608A (es) 2012-01-16
KR20120034710A (ko) 2012-04-12
CL2011003052A1 (es) 2012-08-31
TW201102386A (en) 2011-01-16
TWI464168B (zh) 2014-12-11
EP2438064A1 (en) 2012-04-11
US20100317657A1 (en) 2010-12-16
SG176572A1 (en) 2012-01-30
AU2010255727B2 (en) 2013-02-28
ZA201108439B (en) 2012-08-29
PE20120224A1 (es) 2012-04-04
US20140005163A1 (en) 2014-01-02
UA106074C2 (uk) 2014-07-25
WO2010139731A1 (en) 2010-12-09
ECSP11011500A (es) 2012-01-31
NZ596487A (en) 2012-11-30
CO6470887A2 (es) 2012-06-29
TN2011000626A1 (en) 2013-05-24
EA201101704A1 (ru) 2012-07-30
CN102574845A (zh) 2012-07-11
DOP2011000373A (es) 2011-12-31
AU2010255727A1 (en) 2011-12-08
CA2763821A1 (en) 2010-12-09
US8476294B2 (en) 2013-07-02
JP5596137B2 (ja) 2014-09-24
KR101445458B1 (ko) 2014-10-07
MX2011012943A (es) 2012-01-27
BRPI1010621A2 (pt) 2016-06-21
AR076949A1 (es) 2011-07-20
IL216452A0 (en) 2012-01-31
NI201100209A (es) 2012-02-02
CU24064B1 (es) 2014-12-26
CU20110221A7 (es) 2012-03-15
UY32682A (es) 2011-01-31
CN102574845B (zh) 2015-09-02
MA33332B1 (fr) 2012-06-01
JP2012528828A (ja) 2012-11-15
EA020715B1 (ru) 2015-01-30

Similar Documents

Publication Publication Date Title
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
TW200833675A (en) Nicotinamide derivatives
MX2010005824A (es) Derivados de aminotiazol.
PH12014501804A1 (en) Cycloalkane derivative
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200738655A (en) Novel bicyclic sulfonamide derivatives
TW200833324A (en) Sulfonamide derivatives
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
NZ596615A (en) Substituted isoquinoline derivative
MX2013000362A (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
UA99485C2 (ru) Хиназолиндионовые производные, их получение и их применение в терапии
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
AU2008235282A8 (en) Quinolines and their therapeutic use
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2011012057A (es) Derivados de ciclopenta [c] pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su uso en terapéutica.
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
PH12014502663B1 (en) Aromatic heterocyclic derivative and pharmaceutical
MX2009013003A (es) Derivados de piperidina-amida.